Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1994 Jun;37(6):605–607. doi: 10.1111/j.1365-2125.1994.tb04311.x

Frequency of human CYP2D6 mutant alleles in a normal Chinese population.

E J Lee 1, K Jeyaseelan 1
PMCID: PMC1364822  PMID: 7917781

Abstract

Substantial differences in the pharmacogenetics of debrisoquine hydroxylation exist between Caucasians and Chinese populations. Among Chinese, not only is the frequency of the poor metabolizer phenotype low, the contribution of the 29B mutation in the CYP2D6 gene is insignificant. By contrast the frequency of D6-J is very common (approximately 0.6) and is clearly related to the activity of debrisoquine hydroxylase. Its presence however, does not predict the poor metabolizer phenotype. The D6-C mutation was also not detectable in our population.

Full text

PDF
605

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bertilsson L., Lou Y. Q., Du Y. L., Liu Y., Kuang T. Y., Liao X. M., Wang K. Y., Reviriego J., Iselius L., Sjöqvist F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther. 1992 Apr;51(4):388–397. doi: 10.1038/clpt.1992.38. [DOI] [PubMed] [Google Scholar]
  2. Caporaso N., Pickle L. Debrisoquine phenotype and genotype in Chinese. Lancet. 1989 Dec 23;2(8678-8679):1534–1535. doi: 10.1016/s0140-6736(89)92986-3. [DOI] [PubMed] [Google Scholar]
  3. Eichelbaum M., Spannbrucker N., Steincke B., Dengler H. J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979 Sep;16(3):183–187. doi: 10.1007/BF00562059. [DOI] [PubMed] [Google Scholar]
  4. Evans D. A., Mahgoub A., Sloan T. P., Idle J. R., Smith R. L. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980 Apr;17(2):102–105. doi: 10.1136/jmg.17.2.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Heim M., Meyer U. A. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet. 1990 Sep 1;336(8714):529–532. doi: 10.1016/0140-6736(90)92086-w. [DOI] [PubMed] [Google Scholar]
  6. Johansson I., Yue Q. Y., Dahl M. L., Heim M., Säwe J., Bertilsson L., Meyer U. A., Sjöqvist F., Ingelman-Sundberg M. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol. 1991;40(6):553–556. doi: 10.1007/BF00279968. [DOI] [PubMed] [Google Scholar]
  7. Kagimoto M., Heim M., Kagimoto K., Zeugin T., Meyer U. A. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem. 1990 Oct 5;265(28):17209–17214. [PubMed] [Google Scholar]
  8. Lee E. J., Ang S. B. Measurement of debrisoquine and 4-hydroxydebrisoquine in urine by liquid chromatography. J Pharm Biomed Anal. 1987;5(4):435–439. doi: 10.1016/0731-7085(87)80052-3. [DOI] [PubMed] [Google Scholar]
  9. Lee E. J., Nam Y. P., Hee G. N. Oxidation phenotyping in Chinese and Malay populations. Clin Exp Pharmacol Physiol. 1988 Nov;15(11):889–891. doi: 10.1111/j.1440-1681.1988.tb01032.x. [DOI] [PubMed] [Google Scholar]
  10. Lou Y. C., Ying L., Bertilsson L., Sjöqvist F. Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet. 1987 Oct 10;2(8563):852–853. doi: 10.1016/s0140-6736(87)91034-8. [DOI] [PubMed] [Google Scholar]
  11. Mura C., Broyard J. P., Jacqz-Aigrain E., Krishnamoorthy R. Distinct phenotypes and genotypes of debrisoquine hydroxylation among Europeans and Chinese. Br J Clin Pharmacol. 1991 Jul;32(1):135–136. doi: 10.1111/j.1365-2125.1991.tb05629.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Skoda R. C., Gonzalez F. J., Demierre A., Meyer U. A. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci U S A. 1988 Jul;85(14):5240–5243. doi: 10.1073/pnas.85.14.5240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Steiner E., Bertilsson L., Säwe J., Bertling I., Sjöqvist F. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther. 1988 Oct;44(4):431–435. doi: 10.1038/clpt.1988.176. [DOI] [PubMed] [Google Scholar]
  14. Tyndale R., Aoyama T., Broly F., Matsunaga T., Inaba T., Kalow W., Gelboin H. V., Meyer U. A., Gonzalez F. J. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics. 1991 Oct;1(1):26–32. doi: 10.1097/00008571-199110000-00005. [DOI] [PubMed] [Google Scholar]
  15. Wang S. L., Huang J. D., Lai M. D., Liu B. H., Lai M. L. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther. 1993 Apr;53(4):410–418. doi: 10.1038/clpt.1993.44. [DOI] [PubMed] [Google Scholar]
  16. Yokota H., Tamura S., Furuya H., Kimura S., Watanabe M., Kanazawa I., Kondo I., Gonzalez F. J. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics. 1993 Oct;3(5):256–263. doi: 10.1097/00008571-199310000-00005. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES